Accumulation of liposomal lipid and encapsulated doxorubicin in murine Lewis Lung carcinoma: The lack of beneficial effects by coating liposomes with poly(ethylene glycol)

Journal of Pharmacology and Experimental Therapeutics

Volumn 280, Issue 3, 1997, Pages 1319-1327

  Parr, Michael J ^a,c,f   Masin, Dana ^b   Cullis, Pieter R ^a,e   Bally, Marcel B ^b,d  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d Medical Research Council of   (Canada)

^e Inex Pharmaceuticals Corporation   (Canada)

^f MEDICAL RESEARCH COUNCIL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DISTEAROYLPHOSPHATIDYLCHOLINE; DOXORUBICIN; LIPOSOME; MACROGOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; DOSE RESPONSE; DRUG EXCRETION; DRUG EXPOSURE; FEMALE; LIPID ANALYSIS; LUNG CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; STATISTICAL ANALYSIS; TUMOR GROWTH; TUMOR VOLUME;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CARCINOMA, LEWIS LUNG; CELL DIVISION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG CARRIERS; FEMALE; LIPOSOMES; MICE; POLYETHYLENE GLYCOLS;

EID: 0030973901     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. ABRA, R. M. AND HUNT, C. A.: Liposome distribution in vivo: III. Dose and vesicle size effects. Biochim. Biophys. Acta 666: 493-503, 1981.
2. ALLEN, T. A. AND HANSEN, C.: Pharmacokinetics of stealth vs. conventional liposomes: Effect of dose. Biochim. Biophys. Acta 1068: 133-141, 1991.
3. ALLEN, T. M., HANSEN, C., MARTIN, F., REDEMANN, C. AND YAU-YOUNG, A.: Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. Biochim. Biophys. Acta 1066: 29-36, 1991.
4. ALLEN, T. M., MEHRA, T., HANSEN, C. AND CHIN, Y. C.: Stealth liposomes: and improved sustained release system for 1-β-D arabinofuranosylcytosine. Cancer Res. 52: 2431-2439, 1992.
5. BALAZSOVITS, J. A. E., MAYER, L. D., BALLY, M. B., CULLIS, P. R., MCDONNELL, M., GINSBERG, R. S. AND FALK, R. E.: Analysis of the effect of liposome encapsulation on the vesicant properties, acute and cardiac toxicities, and anti tumor efficacy of doxorubicin. Cancer. Chemother. Pharmacol. 23: 81-86, 1989.
6. BALLY, M. B., NAYAR, R., MASIN, D., CULLIS, P. R. AND MAYER, L. D.: Studies on the myelosuppressive activity of doxorubicin entrapped in liposomes. Cancer Chemother. Pharmacol. 27: 13-19, 1990.
7. BALLY, M. B., MAYER, L. D., HOPE, M. J. AND NAYAR, R.:Pharmacodynamics of liposomal drug carriers: Methodological considerations. In Liposome Technology, 2nd ed., ed. by G. Gregoriadis, vol. III, pp. 27-41, CRC Press, Boca Raton, FL, 1993.
8. BLUME, G. AND CEVC, G.: Liposomes for the sustained drug release in vivo. Biochim. Biophys. Acta 1029: 91-97, 1990.
9. BUTLER, T. P. AND GULLINO, P. M.:Quantification of cell shedding into efferent blood of mammary adenocarcinoma. Cancer Res. 35: 512-516, 1975.
10. DEEHAN, D. J., HEYS, S. D., SIMPSON, W., HERRIOT, R., BROOM, J. AND EREMIN, O.: Correlation of serum cytokine and acute phase reactant levels with alterations in weight and serum albumin in patients receiving immunotherapy with recombinant IL-2. Clin. Exp. Immunol. 95: 366-372, 1994.
11. DAEMEN, T., HOFSTEDE, G., TEN KATE, M. T., BAKKER-WOUDENBERG, I. A. AND SCHERPHOF, G. L.:Liposomal doxorubicin-induced toxicity: depletion and impairment of phagocytic activity of liver macrophages. Int. J. Cancer 61: 716-721, 1995.
12. DERKSEN, J. T. P., MORSELT, H. W. M. AND SCHERPHOF, G. L.: Processing of different liposomes markers after in vivo uptake of immunoglobulin-coated liposomes by rat liver macrophages. Biochim. Biophys. Acta 931: 33-40, 1987.
13. DE VITA, V. T.: Principles of Chemotherapy in Cancer: Principles and Practice of Oncology, 3rd ed., ed. by V. T. De Vita, S. Hellman and S. A. Rosenberg, pp. 276-300, J. B. Lippincott Co., Philadelphia, PA, 1989.
14. FISKE, C. H. AND SUBBAROW, Y.: The colorimetric determination of phosphorous. J. Biol. Chem. 66: 375-400, 1925.
15. FUJITA, S., PURI, R. K., Yu, Z-X., TRAVIS, W. D. AND FERRANS, V. J.: An ultrastructural study of in vivo interactions between lymphocytes and endothelial cells in the pathogenesis of the vascular leak syndrome induced by interleukin-2. Cancer 68: 2169-2174, 1991.
16. GABIZON, A., DAGAN., A., GOREN, D., BARENHOLZ, Y. AND FUKS, Z.: Liposomes as in vivo carriers of adriamycin: reduced cardiac uptake and preserved antitumor activity in mice. Cancer Res. 42: 4734-4739, 1982.
17. GABIZON, A. A.: Selective tumor localization and improved therapeutic index of anthracyclines encapsulated in long-circulating liposomes. Cancer Res. 52: 891-896, 1992.
18. GABIZON, A., CATANE, R., UZIELY, B., KAUFMAN, B., SAFRA, T., COHEN, R., MARTIN, F., HUANG, A. AND BARENHOLZ, Y.: Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-coated liposomes. Cancer Res. 54: 987-992, 1994a.
19. GABIZON, A., ISACSON, R., LIBSON, E., KAUFMAN, B., UZIELY, B., CATANE, R., BEN-DOR, C. G., RABELLO, E., CASS, Y., PERETZ, T., SULKES, A., CHISIN, R. AND BARENHOLZ, Y.: Clinical studies of liposome-encapsulated doxorubicin. Acta Oncol. 33: 779-786, 1994b.
20. GLAVES, D.: Correlation between circulating cancer cells and incidence of metastasis. Br. J. Cancer 48: 665-673, 1983.
21. HERMAN, E. H., RAHMAN, A., FERRANS, V. J., VICK, J. A. AND SCHEIN, P. S.: Prevention of chronic doxorubicin cardiotoxicity in beagles by liposomal encapsulation. Cancer Res. 43: 5427-5432, 1983.
22. HOPE, M. J., BALLY, M. B., WEBB, G. AND CULLIS, P. R.: Production of large unilamellar vesicles by a rapid extrusion procedure: characterization of size, trapped volume and ability to maintain a membrane potential. Biochim. Biophys. Acta 812: 55-65, 1985.
23. HUANG, S. K., MAYHEW, E., GILANI. S., LASIC, D. D., MARTIN, F. J. AND PAPAHADJOPOULOS, D.: Pharmacokinetics and therapeutics of sterically stabilized liposomes in mice bearing C-26 colon carcinoma. Cancer Res. 52: 6774-6781, 1992a.
24. HUANG, S. K., LEE, K.-D., HONG, K., FRIEND. D. S. AND PAPAHADJOPOULOS, D.: Microscopic localization of sterically stabilized liposomes in colon carcinoma-bearing mice. Cancer Res. 52: 5135-5143, 1992b.
25. HUANG, S. K., STAUFFER, P. R., HONG, K., GUO, J. W. H., PHILLIPS, T. L., HUANG, A. AND PAPAHADJOPOULOS, D.:Liposomes and hyperthermia in mice: increased tumor uptake and therapeutic efficacy of doxorubicin in sterically stabilized liposomes. Cancer Res. 54: 2186-2191, 1994.
26. LIN, J. H.:Dose-dependent pharmacokinetics: experimental observations and theoretical considerations. Biopharm. Drug Dispos. 15: 1-31, 1994.
27. LIVINGSTON, R. B.: Dose intensity and high dose therapy. Cancer 74: 1177-1183, 1994.
28. MARUYAMA, K., UNEZAKI, S., TAKAHASHI, N. AND IWATSURA, M.: Enhanced delivery of doxorubicin to tumor by long-circulating thermosensitive liposomes and local hyperthermia. Biochim. Biophys. Acta 1149: 209-216, 1993.
29. MAUK, M. R. AND GAMBLE, R. E.: Stability of lipid vesicles in tissues of the mouse. A γ-ray perturbed angular correlation study. Prod. Natl. Acad. Sci. U.S.A. 76: 765-769, 1979.
30. MAYER, L. D., BALLY, M. B. AND CULLIS, P. R.: Uptake of Adriamycin into large unilamellar vesicles in response to a pH gradient. Biochim. Biophys. Acta 857: 123-126, 1986.
31. MAYER, L. D., BALLY, M. B., LOUGHREY, H., MASIN, D. AND CULLIS, P. R.: Liposomal vincristine preparations which exhibit decreased drug toxicity and increased activity against murine L1210 and P338 tumors. Cancer Res. 50: 575-579, 1990.
32. MAYER, L. D., CULLIS, P. R. AND BALLY, M. B.: The use of transmembrane pH gradient-driven drug encapsulation in the pharmacodynamic evaluation of liposomal doxorubicin. J. Liposome Res. 4: 529-553, 1994.
33. MILLIKEN, G. A. AND JOHNSON, D. E.: Analysis of Messy Data. Vol. 1: Designed Experiments, Van Nostrand Reinhold Co., New York, 1984.
34. NAGARKATTI, M., CLARY, S. AND NAGARKATTI, P. S.: Characterization of tumor-infiltrating CD4+ T cells and Thy 1 cells based on lymphokine secretion and functional properties. J. Immunol. 144: 4898-4905, 1990.
35. NING, S., MACLEOD, K., ABRA, R. M., HUANG, A. H. AND HAHN, G. M.: Hyperthermia induces doxorubicin release from long-circulating liposomes and enhances their anti-tumor efficacy. Int. J. Radiat.Oncol. Biol. Phys. 29: 827-834, 1994.
36. OKU, N., MAMBA, Y. AND OKADA, S.: Tumor accumulation of novel RES-avoiding liposomes. Biochim. Biophys. Acta 1126: 255-260, 1992.
37. M1 in liposomes with entrapped doxorubicin does no prevent RES blockade. Biochim. Biophys Acta 1168: 249-252, 1993.
38. PARR, M. J., ANSELL, S. M., CHOI, L. S. AND CULLIS, P. R.: Factors influencing the retention and chemical stability of poly (ethylene glycol)-lipid conjugates incorporated into large unilamellar vesicles. Biochim. Biophys. Acta 1195: 21-30, 1994.
39. PARR, M. J.: Tumor Accumulation of Liposomes. Ph.D. Thesis, University of British Columbia, Canada, 1995.
40. THOMAS, C., NIJENHUIS, A. M., DONTJE, B., DAEMEN, T. AND SCHERPHOF, G. L.: Tumoricidal response of liver macrophages isolated from rats bearing liver metastases of colon adenocarcinoma. J. Leukocyte Biol. 57: 617-623, 1995.
41. WEBB, M. S., HARASYM, T. O., MASIN, D., BALLY, M. B. AND MAYER, L. D.: Sphingomyelin-cholesterol liposomes significantly enhance the pharmacokinetic and therapeutic properties of vincristine in murine and human tumour models. Br. J. Cancer 72: 896-904, 1995.
42. WU, N. Z., DA, D., RUDOLF, T. L., NEEDHAM, D., WHORTON, A. R. AND DEWHIRST, M. W.: Increased microvascular permeability contributes to preferential accumulation of stealth liposomes in tumor tissue. Cancer Res. 53: 3765-3770, 1993.
43. YUAN, F., LEUNIG, M. HUANG, S. K., BERK, D. A., PAPAHADJOPOULOS, D., AND JAIN, R. K.: Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft. Cancer Res. 54: 3352-3356, 1994.